[Pharmacological and clinical profile of gilteritinib (Xospata tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia].

Gilteritinib fumarate (Xospata tablets 40 mg) is a novel, highly selective, oral FMS-like tyrosine kinase 3 (FLT3) inhibitor used for the treatment of patients with relapsed or refractory FLT3-mutated acute myeloid leukemia (AML), and it was approved in Japan in September 2018. Preclinical studies demonstrated that gilteritinib inhibited FLT3 and showed antiproliferative activity against Ba/F3 cells expressing mutated FLT3. In addition, gilteritinib inhibited tumor growth, induced tumor regression, and prolonged survival in mice xenografted with MV4-11 cells endogenously expressing FLT3-internal tandem duplication.

A dose-ranging study of midazolam for postoperative sedation of patients: a randomized, double-blind, placebo-controlled trial.

Objective: To evaluate the dose range, efficacy, and safety of midazolam for induction of sedation of mechanically ventilated postoperative patients in the intensive care unit.

Design: A randomized, double-blind, placebo-controlled study.

Setting: Thirteen intensive care units in Japan.